Innoviva Price to Free Cash Flow Ratio 2010-2025 | INVA

Historical price to free cash flow ratio values for Innoviva (INVA) since 2010. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Innoviva Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2025-05-23 18.97 6.59
2025-03-31 18.13 $2.88 6.30
2024-12-31 17.35 $2.54 6.83
2024-09-30 19.31 $2.42 7.96
2024-06-30 16.40 $1.94 8.46
2024-03-31 15.24 $1.77 8.60
2023-12-31 16.04 $1.62 9.91
2023-09-30 12.99 $1.35 9.60
2023-06-30 12.73 $1.24 10.26
2023-03-31 11.25 $1.36 8.29
2022-12-31 13.25 $2.12 6.26
2022-09-30 11.61 $2.62 4.43
2022-06-30 14.76 $4.03 3.66
2022-03-31 19.35 $4.16 4.65
2021-12-31 17.25 $3.86 4.47
2021-09-30 16.71 $4.00 4.18
2021-06-30 13.41 $3.08 4.35
2021-03-31 11.95 $2.85 4.19
2020-12-31 12.39 $2.76 4.49
2020-09-30 10.45 $2.60 4.03
2020-06-30 13.98 $2.45 5.72
2020-03-31 11.76 $2.24 5.25
2019-12-31 14.16 $2.27 6.24
2019-09-30 10.54 $2.22 4.74
2019-06-30 14.56 $2.25 6.47
2019-03-31 14.03 $2.21 6.36
2018-12-31 17.45 $1.97 8.85
2018-09-30 15.24 $1.83 8.35
2018-06-30 13.80 $1.66 8.31
2018-03-31 16.67 $1.39 11.98
2017-12-31 14.19 $1.18 12.00
2017-09-30 14.12 $0.95 14.84
2017-06-30 12.80 $0.75 17.01
2017-03-31 13.83 $0.66 20.98
2016-12-31 10.70 $0.49 21.72
2016-09-30 10.99 $0.39 28.54
2016-06-30 10.53 $0.24 43.60
2016-03-31 12.59 $0.17 75.84
2015-12-31 10.54 $0.09 120.05
2015-09-30 7.18 $-1.23 0.00
2015-06-30 17.74 $-1.42 0.00
2015-03-31 15.21 $-1.42 0.00
2014-12-31 13.52 $-2.38 0.00
2014-09-30 16.04 $-2.38 0.00
2014-06-30 27.65 $-2.56 0.00
2014-03-31 23.15 $-2.76 0.00
2013-12-31 26.67 $-2.12 0.00
2013-09-30 30.57 $-1.11 0.00
2013-06-30 28.82 $-1.00 0.00
2013-03-31 17.67 $-1.23 0.00
2012-12-31 16.64 $-1.36 0.00
2012-09-30 19.38 $-1.44 0.00
2012-06-30 16.62 $-1.42 0.00
2012-03-31 14.59 $-1.24 0.00
2011-12-31 16.53 $-1.12 0.00
2011-09-30 15.07 $-1.03 0.00
2011-06-30 16.61 $-1.06 0.00
2011-03-31 18.12 $-1.03 0.00
2010-12-31 18.75 $-1.05 0.00
2010-09-30 15.04 $-0.86 0.00
2010-06-30 9.40 $-0.96 0.00
2010-03-31 9.96 $-0.87 0.00
2009-12-31 9.78 $-0.93 0.00
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.191B $0.359B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $676.409B 51.87
Johnson & Johnson (JNJ) United States $367.985B 15.22
AbbVie (ABBV) United States $323.711B 17.84
Roche Holding AG (RHHBY) Switzerland $253.013B 0.00
Novartis AG (NVS) Switzerland $238.176B 13.60
Merck (MRK) United States $194.806B 9.96
Pfizer (PFE) United States $132.583B 7.26
Sanofi (SNY) France $131.315B 12.56
Bayer (BAYRY) Germany $27.508B 5.60
Novo Nordisk (NVO) Denmark $0.000B 19.93